Image 1
Chemical structure of lansoprazole, showing its molecular formula with indazole, sulfoxide, and trifluoromethyl groups.*
Lansoprazole Capsule, Delayed Release
Product Images NDC 0093-7351
5 FDA label images from Teva Pharmaceuticals Usa, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 0093-7351). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image 2
A line graph depicting the mean severity of day heartburn by study day for evaluable patients, comparing placebo and Lansoprazole 15 mg and 30 mg doses. The y-axis represents mean severity from 0 (none) to 3 (severe), and the x-axis shows days from start of treatment up to 60 days, illustrating a decrease in heartburn severity with Lansoprazole compared to placebo over time.*
Image 3
A line graph titled "Mean Severity of Night Heartburn By Study Day For Evaluable Patients," showing mean night heartburn severity scores (0 to 3 scale) over days from start of treatment (up to 60 days). It compares three groups: Placebo, Lansoprazole 15 mg once daily, and Lansoprazole 30 mg once daily, with heartburn severity decreasing most notably in the Lansoprazole groups over time.*
Image 4
Lansoprazole Delayed-Release Capsules, USP 15 mg label from Teva Pharmaceuticals USA, Inc. The label includes the National Drug Code (NDC) 0093-7350-56, directions for pharmacists to dispense accompanying Medication Guide, and packaging information for 30 capsules. The label also features serialization coding and barcode information and states the product is for oral use and prescription only.*
Image 5
Label of Lansoprazole Delayed-Release Capsules, USP 30 mg by Teva Pharmaceuticals USA, Inc. The label shows the product name, strength (30 mg), dosage form (capsules, delayed release), NDC number 0093-7351-56, and count of 30 capsules. It also includes manufacturer information for Teva Pharmaceuticals, Parsippany, NJ, and storage and dispensing instructions.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
